Web Results


Parties, docket activity and news coverage of federal case KING DRUG COMPANY OF FLORENCE, INC vs. CEPHALON, INC., ET AL, case number 2:06 -cv-01797, from Pennsylvania Eastern Court.


KING DRUG COMPANY OF FLORENCE, INC vs. CEPHALON, INC., ET AL, No. 2 :2006cv01797 - Document 862 (E.D. Pa. 2015) case opinion from the Eastern District of Pennsylvania US Federal District Court.


Mar 29, 2010 ... 216), in King Drug. Co. of Florence, Inc., et ai. v. Cephalon, Inc., et aI., 2:06-cv- 1797. "Defendant Cephalon, Inc. 's Motion to Dismiss the Amended ... et al. v. Cephalon, Inc., et aI., 2:06-cv-1911; Burlington Drug Co., Inc. v. Cephalon, Inc., et aI.,. 2:06-cv-2052; J. M. Smith Corp. v. Cephalon, Inc., et aI., ...


Sep 15, 2015 ... KING DRUG COMPANY. OF FLORENCE, Inc., et al.,. On behalf of themselves and all others similarly situated,. Plaintiffs, v. CEPHALON, INC., et al., ..... Burlington, VT iii. Document Discovery from Non-Parties. 24. Class Counsel served more than a dozen subpoenas on third parties for production.


Aug 17, 2015 ... prescription pharmaceutical Provigilo. All Defendants have denied any wrongdoing. A settlement has been reached between the Direct Purchaser Class Plaintiffs and certain Defendants in the Lawsuit: Defendants Cephalon, Inc., Teva Pharmaceutical. Industries, Ltd., Teva Pharmaceuticals USA, Inc., and ...


Dec 6, 2016 ... SPARTANBURG, SC--(Marketwired - December 06, 2016) - J M Smith Corporation has entered into a merger agreement with Burlington Drug Company and will also purchase certain operations assets of Pharmacy Health Services ( PHS). Once the agreement is completed, in early 2017, they will operate ...


01-MD-1419 (D.N.J) (representing plaintiffs); King Drug Company of Florence, Inc. et al. v. Cephalon, Inc., et al., Civ. No. 2:06-cv-1797 (E.D. Pa.) (representing plaintiffs as to remaining defendants Mylan and Ranbaxy); In re Androgel Antitrust Litigation, MDL Docket No. 1:09-MD-2084 (N.D. Ga.) (representing plaintiffs); In re ...


See Mark L. Kovner et al., Applying the Noerr Doctrine to Pharmaceutical Patent. Litigation ... Drug Co. v. Geneva Pharm., Inc., 344 F.3d 1294, 1309 (11th Cir. 2003); In re Ciprofloxacin. Hydrochloride Antitrust Litig. (Cipro II), 363 F. Supp. 2d 514, 520 n.6 (E.D.N.Y. 2005). 10. See In re ... 2006); Burlington Drug Co. v.


Attention-deficit/hyperactivity disorder (ADHD) is a common psychiatric disorder characterized by symptoms of hyperactivity, impulsivity, and inattention that begin in early childhood and continue to cause impairment into adolescence and young adulthood (Manuzza et al. 1997; Barkley et al. 2002; Biederman and Faraone ...